Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

als, Inc. and Alkermes, Inc., submitted a reply to a complete response letter issued in October 2010 by FDA regarding Bydureon™, an investigational medication for type 2 diabetes. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date of January 28, 2012.
  • The company submitted its reply to a complete response letter by FDA regarding Amyvid™, a molecular Positron Emission Tomography (PET) imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients.

  • The America Invents Act was signed into law, aligning new U.S. patent laws more closely with those from other countries and improving the global competiveness of U.S. innovator companies such as Lilly. The law will provide new advantages for U.S. inventors by streamlining the application process and addressing the backlog of current applications. This new law, which transitions the U.S. from a "first-to-invent" to a "first-inventor-to-file" system, is the most significant overhaul of the U.S. patent system in 175 years.

  • Third-Quarter Reported Results

    In the third quarter of 2011, worldwide total revenue was $6.148 billion, an increase of 9 percent compared with the third quarter of 2010. This 9 percent revenue growth was comprised of increases of 4 percent in volume and 4 percent due to the impact of foreign exchange rates. Price had a negligible impact on revenue growth, reflecting the loss of U.S. patent exclusivity for Gemzar® in November 2010. Total revenue in the U.S. increased 4 percent to $3.273 billion due to higher prices and increased volume. Total revenue outside the U.S. increased 15 percent to $2.874 billion due to the positive impact of foreign exchange rates and increased volume. Third-quarter 2011 total revenue was reduced by approximately $130 million due to the impact of U.S. health care reform.

    Gross margin increased 3.1 percent to $4.810 billion in the third quarte
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Lilly Declares Fourth-Quarter 2011 Dividend
    2. Lilly Announces Changes in Senior Management
    3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
    4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
    5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
    6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
    7. Lilly Health Channel Debuts on YouTube
    8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
    9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
    10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
    11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... successfully used to save millions of lives across globe. ... the Kingdom of Saudi Arabia . ... raw material suppliers, government agencies and regulatory bodies. The ... been studied from two perspectives: by products and by ...
    (Date:9/3/2015)... Sept. 3, 2015  WellCare Health Plans, Inc. (NYSE: ... , senior vice president and chief financial officer, is ... Healthcare Conference on Wednesday, September 9, 2015, at 9:25 ... webcast live. In addition, a replay of the webcast ... broadcast. Both the live broadcast and the replay will ...
    (Date:9/3/2015)... RICHMOND, Va. , Sept. 3, 2015  As ... for patients with heart disease, Marc R. Katz ... of the Bon Secours Heart & Vascular Institute implanted ... August 18, 2015. The patient was selected as part ... is one of 60 elite centers in the United ...
    Breaking Medicine Technology:Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 2Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 3Bon Secours' Patient FIRST in Central Virginia to receive New Life-saving Care 4
    ... BERGISCH GLADBACH, Germany, May 20 Miltenyi ... Myelin Removal Beads. Myelin,is a specialized membrane ... and central nervous system. During preparation of ... contaminant. "When,dissociating adult neural tissue, usually less ...
    ... New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) ... relapse compared to placebo in patients with Bipolar I ... at a major medical meeting. Bipolar Disorder is ... person,s mood, energy and ability to function. It is ...
    Cached Medicine Technology:Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
    (Date:9/3/2015)... ... 03, 2015 , ... BedJet released a new version of its award winning ... Today the BedJet v2 pre-order campaign blazed past the $1 million dollar ... ever on crowdfunding giant Kickstarter. , Simple to use and beautifully designed, the award ...
    (Date:9/3/2015)... ... September 03, 2015 , ... Real Time Pain Relief (RTPR), ... bull rider David Mason has signed an official endorsement deal with the company. Originally ... six and his first bull at 15. He is an Australian bull riding champion, ...
    (Date:9/3/2015)... ... 2015 , ... Hope For The Warriors® is pleased to ... awarded two times each year to spouses or caregivers of post-9/11 wounded or ... restoring a sense of self, restoring the family unit, and restoring hope for ...
    (Date:9/3/2015)... GA (PRWEB) , ... September 03, 2015 , ... ... cover the cost of graduated compression garments. However, graduated compression garments are an ... Wound care and lymphedema specialist, Robyn Bjork, was recently sponsored by SIGVARIS ...
    (Date:9/3/2015)... ... September 03, 2015 , ... ... landscape by connecting accredited and institutional investors to real estate investment opportunities nationwide, ... to meet demand from both investors and sponsoring real estate companies. ...
    Breaking Medicine News(10 mins):Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3
    ... taken necessary steps and planned a schedule to support employed ... that women took leave from work very often to take ... schedule of work and increased their stress level. ... wide rage of medical problems. The news paper said that ...
    ... medical marijuana, concerns have been raised by justices regarding allowing ... symptoms and perhaps even prolong life. A federal appeals court ... legal wrangling over the issue, this week. ,The ... the drug should be allowed, it is the only viable ...
    ... Statistics show that about one in 100 11-year-olds had taken ... and one in 10 of 15-year-olds// have taken hard drugs. ... pupils. They take illegal drugs such as cocaine which has ... , The survey was carried out among England's 3.4 million ...
    ... getting sensitive to noise, and do not like it much! ... noisy surroundings// may face an increased risk of suffering a ... chances of urban middle-aged adults, living on high-traffic ... percent chance of suffering heart attack, than those who lived ...
    ... Even though mental disorders are said to account for ... studies have been undertaken to assess// this assumption in ... as part of the WHO World Mental Health (WMH) ... 2857 adults was done in Lebanon between September, 2002, ...
    ... The new low nicotine Quest? cigarettes seems to have ... to a study conducted by researchers// at the Transdisciplinary ... School of Medicine.Results of the study have been published ... ,The author of this study, Caryn Lerman, PhD, Associate ...
    Cached Medicine News:Health News:Cancer Patient to Appeal to SC, Demanding Right to Use Marijuana 2Health News:A National Survey Revealed That Mental Disorders Are Common In Lebanon 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: